Overview
- Azitra disclosed a securities purchase agreement that provides approximately $10.5 million upfront and up to $31.4 million in gross proceeds if warrants are exercised.
- Investors include Stonepine Capital, Nantahala Capital, other healthcare-focused funds, and company insiders, who are buying Series A convertible preferred stock at $1,000 per share plus Series B and C warrants at $0.123.
- The company said the transaction is expected to close on or around Friday and that initial net proceeds will support R&D, general corporate needs, and working capital.
- AZTR jumped 28.82% to close at $0.18 on Thursday and rose a further 44.24% after hours to $0.25, with separate reports noting an intraday move of up to 87% on Friday and a spike in trading volume.
- Management frames the funding as a runway to advance filaggrin-based cosmetic ingredients addressing skin barrier dysfunction, while the stock remains a small-cap with a steep year-over-year decline and a NYSE American equity-compliance warning reported.